Federal Register / Vol. 72, No. 106 / Monday, June 4, 2007 / Notices 30805 

decision making that is transparent and 

involves the broad stakeholder 

communities. 

8. Timely—Have the ability to carry 

out activities and achieve goals in a 

timely manner. 

9. Collaborative—Have the ability to 

engage and work with other 

organizations to ensure effective 

implementation of rules and standards. 

10. Sustainable—Have adequate 

resources to meet long and short term 

goals. 

The concept of a national entity 

responsible for setting rules and 

standards for sharing and using 

healthcare quality measurement data 

has also been supported by the Institute 

of Medicine in their 2005 report 

Performance Measurement. IOM 

additionally proposed that this entity 

would be responsible for several other 

roles in performance measurement, 

including articulation of national goals, 

selection of measures, aggregation of 

data, reporting of results and 

performance measurement research. It is 

recognized that the role of a NHDSE 

might extend to domains beyond health 

care performance measurement. 

Respondents are encouraged to describe 

such domains and provide information 

relating to NHDSE roles and 

characteristics, with the understanding 

that any such information will be 

considered and will be presented by 

AHRQ to AQA but may not be acted on 

in the immediate future. 

Information Requested 

For the purpose of achieving a 

broader understanding of the need for a 

nationwide health data stewardship 

entity, and what form it might take, 

input is requested from interested 

parties. It is not necessary to answer all 

questions. In your response, please 

indicate which question you are 

addressing in your comments. Specific 

areas for comment include: 

1. Whether or not there is a need for 

a national health data stewardship 

entity with reasons, including value 

such an entity might bring and issues it 

might solve 

2. Desirable governmental and private 

sector roles in such an organization or 

in health data stewardship more 

generally 

3. The roles and responsibilities 

currently assumed by other existing 

entities that might be addressed by a 

NHDSE, as well as roles that should not 

be fulfilled by a NHDSE 

4. The relationship of a NHDSE and 

its work to other quality improvement 

organizations and activities 

5. The relationship of a NHDSE and 

its work to other initiatives which set 

national standards for health 

information, such as the ANSI Health IT 

Standards Panel (HITSP) 

6. Key challenges to creation and 

maintenance of a NHDSE 

7. The risks of creating a NHDSE 

8. The appropriate role(s) of a NHDSE 

in advancing quality measurement 

9. The appropriate role(s) of a NHDSE 

in characterization and evaluation of the 

comprehensiveness, accuracy and 

reliability of shared and aggregated 

health care quality measurement data 

10. The appropriate role(s) of a 

NHDSE regarding the transmission of 

shared and aggregated data 

11. The appropriate scope of activities 

for a NHDSE beyond quality 

measurement (in such domains as 

research and population health) 

12. The key stakeholders that would 

be impacted by a NHDSE and how to 

structure interactions with a NHDSE 

13. Appropriate governance model(s) 

for a NHDSE 

14. Means to assure NHDSE 

objectivity and independence 

15. Means to achieve trustworthiness 

or trust in a NHDSE, and how that 

would best be achieved 

16. Recommendations for achieving 

timeliness in NHDSE decision making 

17. Recommendations for achieving 

compliance with NHDSE 

recommendations, rules or standards 

18. The essential external inputs to a 

NHDSE 

19. Recommendations for achieving 

organizational flexibility for a NHDSE 

20. The potential organizational 

infrastructure needs of a NHDSE 

21. Potential funding requirements 

and sources of funding for a NHDSE 

22. The organizational skill set 

required of a NDHSE 

23. Priority activities for NHDSE to 

support data sharing and aggregation 

24. Issues concerning the aboveexcerpted AQA characterizations of a 

NHDSE 

25. The suitability of one or more 

existing organizations to fulfill the role 

of a NHDSE 

Potential Responders 

Responses are both requested and 

anticipated from a broad range of 

individual organizations that have 

interests in healthcare data. Examples of 

commenters from whom we would hope 

to hear include, but are not limited to: 

Health care professional societies 

Payers, including public and private 

insurers 

Health maintenance organizations 

Purchasers, including employers and 

healthcare consumers 

Consumer and patient interest groups 

Community health delivery systems 

State and local health agencies 

Interested Federal agencies 

University-based health systems 

Advocacy groups and public interest 

organizations 

Trade industry organizations 

Health information technology industry 

vendors 

Regional health information 

organizations 

Interested individuals 

We look forward to receiving 

constructive comments representing 

diverse perspectives. 

Dated: May 25, 2007. 

Carolyn M. Clancy, 

AHRQ, Director. 

[FR Doc. 07–2733 Filed 6–1–07; 8:45 am] 

BILLING CODE 4160–90–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Administration for Children and 

Families 

Proposed Information Collection 

Activity; Comment Request 

Proposed Projects: 

Title: Communities Empowering 

Youth (CEY) Program Evaluation. 

OMB No.: New collection. 

Description: This proposed 

information collection activity is to 

obtain information from Communities 

Empowering Youth (CEY) grantee 

agencies and the faith-based and 

community organizations working in 

partnership with them. The CEY 

evaluation is an important opportunity 

to examine the outcomes achieved 

through this component of the 

Compassion Capital Fund in meeting its 

objective of improving the capacity of 

faith-based and community 

organizations and the partnerships they 

form to increase positive youth 

development and address youth 

violence, gang involvement, and child 

abuse/neglect. The evaluation will be 

designed to assess changes and 

improvements in the structure and 

functioning of the partnership and the 

organizational capacity of each 

participating organization. 

Respondents: CEY grantees and the 

faith-based and community 

organizations that are a part of the 

partnership approved under the CEY 

grant. 


rwilkins on PROD1PC63 with NOTICES
30806 Federal Register / Vol. 72, No. 106 / Monday, June 4, 2007 / Notices 

ANNUAL BURDEN ESTIMATES

Instrument Number of 

respondents 

Number of responses per 

respondent 

Average 

burden hours 

per response 

Total burden 

hours 

Initial/Baseline Survey ..................................................................................... 800 1 .75 600 

Follow-up Survey ............................................................................................. 640 1 .75 480 

Estimated Total Annual Burden 

Hours: 1,080. 

In compliance with the requirements 

of Section 3506(c)(2)(A) of the 

Paperwork Reduction Act of 1995, the 

Administration for Children and 

Families is soliciting public comment 

on the specific aspects of the 

information collection described above. 

Copies of the proposed collection of 

information can be obtained and 

comments may be forwarded by writing 

to the Administration for Children and 

Families, Office of Administration, 

Office of Information Services, 370 

L’Enfant Promenade, SW., Washington, 

DC 20447. Attn: ACF Reports Clearance 

Officer. Email address: 

infocollection@acf.hhs.gov. All requests 

should be identified by the title of the 

information collection. 

The Department specifically requests 

comments on: (a) Whether the proposed 

collection of information is necessary 

for the proper performance of the 

functions of the agency, including 

whether the information shall have 

practical utility; (b) the accuracy of the 

agency’s estimate of the burden of the 

proposed collection of information; (c) 

the quality, utility, and clarity of the 

information to be collected; and (d) 

ways to minimize the burden of the 

collection of information on 

respondents. Consideration will be 

given to comments and suggestions 

submitted within 60 days of this 

publication. 

Dated: May 29, 2007. 

Brendan C. Kelly, 

Reports Clearance Officer. 

[FR Doc. 07–2724 Filed 6–1–07; 8:45 am] 

BILLING CODE 4184–01–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Government-Owned Inventions; 

Availability for Licensing 

AGENCY: National Institutes of Health, 

Public Health Service, HHS. 

ACTION: Notice. 

SUMMARY: The inventions listed below 

are owned by an agency of the U.S. 

Government and are available for 

licensing in the U.S. in accordance with 

35 U.S.C. 207 to achieve expeditious 

commercialization of results of 

Federally-funded research and 

development. Foreign patent 

applications are filed on selected 

inventions to extend market coverage 

for companies and may also be available 

for licensing. 

ADDRESSES: Licensing information and 

copies of the U.S. patent applications 

listed below may be obtained by writing 

to the indicated licensing contact at the 

Office of Technology Transfer, National 

Institutes of Health, 6011 Executive 

Boulevard, Suite 325, Rockville, 

Maryland 20852–3804; telephone: 301/ 

496–7057; fax: 301/402–0220. A signed 

Confidential Disclosure Agreement will 

be required to receive copies of the 

patent applications. 

Human and Avian Influenza Whole 

Genome Phage Display Libraries 

Description of Technology: Available 

for use in developing research reagents, 

therapeutics or diagnostics are 

recombinant bacteriophage display 

libraries for identifying influenza viral 

gene products in preparation for 

pandemic threats the cross-reactivity 

and long-term protection of 

interpandemic influenza vaccines. 

Influenza vaccines predominantly 

include haemagglutinin (HA) and 

Neuraminidase (NA) antigens that 

characterize annual circulating 

influenza types A and type B. Analyses 

of the immune responses against new 

candidate vaccines is required in order 

to identify the best correlate of 

protection against seasonal human 

influenza strains and potential 

pandemic strains. 

These ‘‘Whole Viral Genome Phage 

Display Libraries’’ express complete sets 

of protein fragments encoded by several 

Human and Avian Influenza strains 

including HlN1, H3N2, H5N1 and H7N7 

and can be used for in depth analyses 

of plasma samples from: (a) Individuals 

exposed to human influenza; (b) 

individuals exposed to avian influenza; 

(c) individuals vaccinated with 

traditional influenza vaccines; (d) 

individuals vaccinated with new 

generation vaccines against human and 

bird influenza viruses. 

Applications: Serological assays for 

surveillance of pandemic influenza 

outbreaks; Serological assays for 

distinguishing between exposure to 

human and bird influenza strains; 

Serological assays for diagnosing true 

infections in previously vaccinated 

individuals; Rapid analyses of immune 

sera from pre-clinical and clinical trials 

of novel influenza vaccines; Mapping of 

monoclonal and polyclonal antibodies 

against different influenza gene 

products; Identification of highly 

conserved ‘‘protective’’ epitopes for 

inclusion in future broadly-reactive 

influenza vaccines (against either interpandemic or pandemic influenza 

strains); Studies of viral protein-protein, 

viral RNA-protein and viral-host protein 

interactions (viral pathogenesis studies). 

Market: Influenza diagnostics and 

vaccines. 

Development Status: Materials 

available as research tools. 

Inventors: Hana Golding, Ph.D. (FDA), 

Surender Khurana, Ph.D. (FDA). 

Patent Status: HHS Reference No. E–

031–2007/0—Research Tool. 

Licensing Status: Available for 

licensing as a biological material. 

Scientific Contact: Hana Golding, 

Ph.D.; FDA/CBER/OVRR/DVP/LR; 9000 

Rockville Pike, Building 29B, Room 

4N04, Bethesda, MD 20892; E-mail: 

goldingh@cber.fda.gov; Phone: 301/827–

0784. 

Licensing Contact: Michael A. 

Shmilovich, Esq.; National Institutes of 

Health, Office of Technology Transfer; 

6011 Executive Blvd., Suite 325, 

Rockville, MD 20852; E-mail: 

shmilovm@mail.nih.gov; Phone: 301/ 

435–5019; Fax: 301/402–0220. 

Diagnostic and Therapeutic Use of 

Brother of the Regulator of Imprinted 

Sites (BORIS) Alternative Splice Forms 

Description of Technology: This 

technology identifies twenty five (25) 

new alternatively spliced transcripts of 

the BORIS gene. The transcripts lead to 

the expression of seventeen different 

protein isoforms with variable N- and Ctermini encoded by BORIS gene locus. 

Differential expression levels of BORIS 

isoforms were observed in different 

cancers. While some BORIS alternative 

splice variants were expressed at 

different levels in all types of cancers, 


rwilkins on PROD1PC63 with NOTICES